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Association of Aβ with ceramide-enriched
astrosomes mediates Aβ neurotoxicity
Ahmed Elsherbini1, Alexander S. Kirov2, Michael B. Dinkins2, Guanghu Wang1, Haiyan Qin1, Zhihui Zhu1,
Priyanka Tripathi1, Simone M. Crivelli1 and Erhard Bieberich1*
Abstract
Amyloid-β (Aβ) associates with extracellular vesicles termed exosomes. It is not clear whether and how exosomes
modulate Aβ neurotoxicity in Alzheimer’s disease (AD). We show here that brain tissue and serum from the
transgenic mouse model of familial AD (5xFAD) and serum from AD patients contains ceramide-enriched and
astrocyte-derived exosomes (termed astrosomes) that are associated with Aβ. In Neuro-2a cells, primary cultured
neurons, and human induced pluripotent stem cell-derived neurons, Aβ-associated astrosomes from 5xFAD mice
and AD patient serum were specifically transported to mitochondria, induced mitochondrial clustering, and
upregulated the fission protein Drp-1 at a concentration corresponding to 5 femtomoles Aβ/L of medium. Aβ-
associated astrosomes, but not wild type or control human serum exosomes, mediated binding of Aβ to voltage-
dependent anion channel 1 (VDAC1) and subsequently, activated caspases. Aβ-associated astrosomes induced
neurite fragmentation and neuronal cell death, suggesting that association with astrosomes substantially enhances
Aβ neurotoxicity in AD and may comprise a novel target for therapy.
Keywords: Astrocytes, Exosomes, Mitochondria, Ceramide, Amyloid
Introduction
Aβ plaque deposits and tau neurofibrillary tangle forma-
tion are hallmarks of AD [2, 62]. However, it is still
controversial which of the two factors is critical for
neuronal dysfunction and death, ultimately leading to
cognitive decline and demise of the patient. Most of the
previous studies assumed that the buildup of Aβ or tau
by themselves induces neurotoxicity [47, 55, 70]. This
assumption, however, was in stark contrast to observa-
tions in AD mouse models and patients showing signifi-
cant buildup of plaques and tangles without obvious
neuronal cell death [62]. We hypothesized that neuro-
toxicity of Aβ is mediated by its interaction with an
unknown factor. Based on our previous studies showing
that Aβ associates with astrocyte-derived exosomes (here
termed astrosomes), we tested if this interaction mediates
neurotoxicity of Aβ [15, 71].
Exosomes are generated as intraluminal vesicles of
multivesicular endosomes and secreted as a type of
extracellular vesicles by a large variety of cells and
tissues [12, 13, 74]. Exosomes are deemed to serve as
carriers for the intercellular transport of micro RNAs
and some proteins. Although their size of 100 nm favors
a high membrane surface-to-volume ratio, the role of
membrane lipids in exosomes remains largely un-
explored [18, 21, 67]. Our laboratory discovered that the
sphingolipid ceramide is enriched in the membrane of
astrosomes [71]. We also showed that ceramide mediates
association of Aβ with astrosomes and that this associ-
ation leads to astrosome aggregation in vitro, a process
we suggested to nucleate amyloid plaques in AD brain
[15]. However, we do not know if amyloid plaque
nucleation is the only or even main function of astro-
somes. Recent studies demonstrated that Aβ-associated
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exosomes cross the blood-brain-barrier and are detect-
able in serum from AD mice and patients [25, 53, 63]. In
fact, exosomes purified from patient serum are proposed
as AD biomarkers that are detectable up to a decade
prior to clinical symptoms of cognitive decline [25].
While a proportion of serum exosomes is clearly derived
from brain, composition and function of these exosomes
remains largely unknown.
In the current study using mass spectrometry and
anti-ceramide antibody, we found that a proportion of
serum-derived serum exosomes is enriched with the
same ceramide species previously detected in astrosomes
isolated from primary astrocyte culture [15]. We also
isolated exosomes from wild type and 5xFAD brain tis-
sue and confirmed the astrocytic origin and Aβ associ-
ation of tissue and serum-derived exosomes by testing
for the presence of the astrocyte marker glial fibrillary
acidic protein (GFAP) and Aβ. Aβ-associated astrosomes
were taken up by neural cells and specifically trans-
ported to mitochondria, thereby inducing mitochondrial
damage and caspase activation. Most importantly, the
concentration of Aβ associated with astrosomes inducing
damage was several orders of magnitude lower than
required when using Aβ without astrosomes. Aβ-
associated astrosomes induced formation of a pro-
apoptotic complex between Aβ and voltage-dependent
anion channel 1 (VDAC1), the main ADP/ATP trans-
porter in the outer mitochondrial membrane [50, 65].
These results suggest that astrosomes are the unknown
factor mediating neurotoxicity of Aβ by inducing mito-
chondrial damage and apoptosis. Our data also indicate
that Aβ-associated exosomes may comprise a novel
pharmacological target for AD therapy.
Materials and methods
Cell cultures
The N2a cell line was obtained from ATCC (CCL-131™).
The cells were grown to 90% confluence at 37 °C and 5%
CO2 atmosphere in Dulbecco’s modified Eagle’s medium
(DMEM) (Gibco, Invitrogen, CA, USA) supplemented
with 10% fetal bovine serum (FBS) on 100 mm plates
(Corning, MA, USA). For immunocytochemistry ana-
lyses, cells were seeded on poly-L-lysine (Milipore-
Sigma, Montana, USA) coated cover slips at 10,000
cells/cover slip. Cells were gradually deprived of serum
to allow for differentiation into neuron-like cells.
Incubation with exosomes was always performed under
serum-free conditions.
Primary neurons were isolated from E16.5-P0 mouse
cortices following 30 min trypsinization and trituration
with a flame-polished Pasteur pipet. Neurons were
plated on polyethylene imine coated T-25 flasks as previ-
ously described [15] and maintained 7 days in Neuroba-
sal medium with B27 supplement (Life Technologies)
prior to incubation with exosomes. To cultivate human
induced pluripotent stem (iPS) cell-derived neuropro-
genitor (NP) cells, the ReNcell VM Human NP cell line
was obtained from Millipore (Temecula, CA, USA, Cat#
SCC008). Cells were maintained according to the sup-
plier’s protocol. Briefly, cells were expanded on laminin-
coated 100 mm tissue culture dishes (Corning) in
ReNcell NSC maintenance medium (Millipore) supple-
mented with 20 ng/mL fibroblast growth factor–2 (FGF-
2) and 20 ng/mL epidermal growth factor (EGF) (Milli-
pore). The medium was changed daily during the main-
tenance period. The cells were passaged once a week
using Accutase (Millipore). Cells were then differentiated
by seeding them at around 60% confluency on freshly
laminin-coated dishes and growing overnight in the
presence of growth factors, followed by withdrawal of
growth factors. The media were replaced every other day
up to 10 days during the differentiation period.
Serum exosome isolation, quantification, and labeling
All experiments using mice were carried out according
to an Animal Use Protocol approved by the Institutional
Animal Care and Use Committee at University of
Kentucky. Sera were isolated from freshly obtained
mouse blood. Human exosomes were isolated from sera
obtained from the University of Kentucky Alzheimer
Disease Center.
DX SEX AGE BMI Collection Date Sample Type
NORMAL Male 75 27 3/4/2009 Serum
NORMAL Male 75 25.56 5/7/2009 Serum
NORMAL Male 75 26.1 11/3/2010 Serum
DEMENTED Male 74 27.28 2/27/2002 Serum
DEMENTED Male 75 29.41 5/7/2003 Serum
DEMENTED Male 74 25 3/23/2005 Serum
Mouse blood was drawn through heart puncture and
was allowed to clot at room temperature for 30 min.
Blood was then centrifuged at 1800 x g for 10 min at
4 °C. The clear upper layer was transferred to a fresh
tube and centrifuged at 3000 x g for 15 min to pellet
residual blood cells. Exosomes were extracted using
ExoQuick exosome solution (EXOQ; System
Biosciences, Inc., Mountain View, CA, USA) according
to the manufacturer’s protocol. Briefly, 250 μl aliquots of
serum were treated with 67 μl of ExoQuick exosome
solution, followed by incubation for 60 min at 4 °C to
precipitate total exosomes. Tubes were then centrifuged
at 1500 x g for 30 min. Each exosome pellet was
resuspended in 100 μl of PBS with 1X Halt™ Protease
Inhibitor Cocktail (Thermo Fisher, Massachusetts, USA).
In certain experiments exosomes were labeled with
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PKH67 Green Fluorescent Dye using the Green
Fluorescent Cell Linker Kit for General Cell Membrane
Labelling (Sigma-Aldrich) according to the manufacturer’s
protocol. Briefly, ExoQuick pellets were resuspended in
PBS, 1ml of Diluent C (CGLDIL, Sigma-Aldrich) was then
added to each sample. As a control, 1 ml of Diluent C after
adding the same volume of PBS was used. Next, 4 μl of
PKH67 dye was added to 1ml of Diluent C then mixed
with the exosomes and the control, PKH67/Diluent C
mixture was ultra-centrifuged before being added to
samples. The samples were allowed to incubate < 5 min
on a rotor plate. One ml of 1% BSA was then added to
bind excess dye. Samples were ultra-centrifuged at 110,
000 xg for 70 min, washed and centrifuged again. For
exosome quantification, nanoparticle tracking analysis
(NTA) with the ZetaView PMX110 (Particle Metrix)
was used. Briefly, exosomes were resuspended in PBS.
Two ml of appropriately diluted samples were injected
into the ZetaView cell. The instrument was set to
obtain NTA measurements at 11 positions, two cycles
at each position. During acquisition, temperature was
set to 23 °C, camera sensitivity to 82, 30 frames/s, and
shutter speed to 250. Polystyrene beads (100 nm) were
used for instrument calibration. For exosome incubation
with ceramide analogs N-oleoyl serinol (S18 or bis
palmitoyl ethanolamine (B16) the exosomes prepared
from 5xFAD or control serum were incubated at
37 °C for 16 h with 50 μMS18 or B16.
In addition to the ExoQuick exosome isolation
method, we used the Exoeasy Maxi kit (Qiagen,
Germany) to isolate exosomes from sera following the
manufacturer’s protocol. Briefly, sera were diluted with
an equal volume of distilled water to reduce viscosity
and they were passed through a 0.45 μm filter to remove
larger particles. 1 volume of Exoeasy binding buffer
(XBP) was then added to 1 volume of sample. Sample/
XBP mix was added onto the Exoeasy spin column and
centrifuged at 500 x g for 1 min. Flow-through was dis-
carded and the columns were placed back into the same
collection tube. Ten ml Exoeasy washing buffer (XWP)
were then added to columns, followed by centrifugation
at 500 x g for 5 min to remove residual buffer from the
column. Flow-through together with the collection tube
were discarded. Spin columns were transferred to fresh
collection tubes. Four hundred μl of elution buffer were
added to the membrane and incubated for 1 min,
followed by centrifugation at 500 x g for 5 min to collect
the eluate.
Brain exosome isolation
This method is a modification to the protocol described
by Miltenyi Biotic for isolation and cultivation of
astrocytes from adult mouse brain utilizing gentleMACS
Octo Dissociator. Briefly, mice were anesthetized using
isoflurane inhalation in a chamber followed by perfusion
of the whole body with cold 1x PBS to remove blood-
derived exosomes from the brain. Mice brains were col-
lected, washed with 1x PBS and cut into eight sagittal
slices using sterile scalpel in a petri dish. Brain slices
were then transferred to C tubes containing enzymatic
dissociation buffer. C tubes were tightly closed and at-
tached upside down onto the sleeves of the gentleMACS
Octo Dissociator with Heaters, Program 37C_ABDK_01
being used. Samples were resuspended and applied to a
MACS SmartStrainer (70 μm) placed on a 50 mL tube.
10 mL of cold D-PBS were applied onto the MACS
SmartStrainer (70 μm). Cell suspensions were centri-
fuged at 300×g for 10 min at 4 °C, supernatants were
carefully transferred to a fresh tube to proceed with exo-
some isolation. Supernatants were centrifuged at 2000×g
for 10 min followed by 10,000×g for 30–40 min then
passed through a 0.45 μm filter before following the
Exoeasy exosome isolation protocol as described above.
Immunocytochemistry
N2a, primary cultured neurons, or human
neuroprogenitor cells were seeded on poly-L-lysine
coated cover slips at a density of 25,000 cells/cover slip.
N2a cells were allowed to differentiate by gradual serum
deprivation [23]. Two days prior to exosome incubation,
exosome-free FBS (EXO-FBS - System Biosciences,
Mountain View, CA, USA) was used to supplement the
media. Cells were then incubated with exosomes and
washed three times with PBS, followed by fixation with
4% p-formaldehyde containing 0.5% glutaraldehyde in
PBS for 15 min at room temperature. Permeabilization
was performed by incubation with 0.2% Triton X-100 in
PBS for 5 min at room temperature. Non-specific bind-
ing sites were blocked with 3% ovalbumin/PBS for 1 h at
37 °C. Cells were then incubated with primary antibodies
at 4 °C overnight. The next day, cells were washed with
PBS and incubated with secondary antibodies diluted 1:
300 in 0.1% ovalbumin/PBS for 2 h at 37 °C. Secondary
antibodies were Cy2-conjugated donkey anti-mouse
IgM, Alexa Fluor 546-conjugated donkey anti-rabbit
IgG, and Alexa Fluor 647-conjugated goat anti-mouse
IgG (Jackson ImmunoResearch, West Grove, PA). After
washing, cover slips were mounted using Fluoroshield
supplemented with DAPI (Sigma-Aldrich) to visualize
the nuclei. We used the following primary antibodies:
anti-ceramide rabbit IgG (1:100, our laboratory), anti-
flotillin-2 mouse IgG (1:300 BD Biosciences, California,
USA, 610383), anti-amyloid-beta mouse IgG 4G8 clone
(1:200 Biolegends, California, USA, SIG-39220), beta
amyloid recombinant rabbit monoclonal antibody
(H31L21, Thermo Fisher), anti-GFAP mouse IgG (1:500,
abcam, Cambridge, MA, USA, ab10062), anti-Tom 20
rabbit IgG (1200, Santa Cruz, sc-11,415), anti-VDAC1
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rabbit IgG (1500, Abcam, ab15895). Fluorescence mi-
croscopy was performed using Eclipse Ti2-E inverted
microscope system (Nikon, New York, USA). Images
were processed using Nikon NIS-Elements software
equipped with a 3D deconvolution program. Pearson’s
correlation coefficient for two fluorescence channels in
overlays was used to assess the degree of colocalization.
Proximity ligation assay
Cells were grown and treated as described above in the
protocol for immunocytochemistry. Non-specific bind-
ing sites were blocked with Duolink PLA blocking solu-
tion (Sigma-Aldrich) for 1 h at 37 °C. The primary
antibodies used were; anti-Aβ mouse IgG (1:500 4G8,
Biolegends, California, USA, SIG-39220), anti-VDAC1
rabbit IgG (1:1000 abcam, Cambridge, MA, USA,
ab34726) Secondary PLA probes: anti-mouse MINUS
affinity-purified donkey anti-mouse IgG (H + L) and
anti-rabbit PLUS affinity-purified donkey anti-rabbit IgG
(H + L) were diluted 1:5 in antibody diluent buffer and
samples incubated for 1 h at 37 °C followed by ligation
and amplification steps as described in the manufac-
turer’s protocol (Duolink, Sigma-Aldrich). Cover slips
were mounted using Fluoroshield supplemented with
DAPI (Sigma-Aldrich) to visualize the nuclei. Images ob-
tained with secondary antibody only were used as nega-
tive controls representing the background intensity in a
laser channel. ImageJ software (https://imagej.nih.gov/ij/
) was used to analyze the pictures. Two channels (DAPI
and TRITC) were separated to analyze nuclear staining
(DAPI) of the images separately from the TRITC-
channel associated with the PLA dots. Firstly, threshold
was set in order to identify nucleus and to allow for bin-
ary conversion (black and white). Morphological func-
tion was used to separate touching nuclei. Nuclei were
counted and added to the region of interest (ROI) where
the appropriate minimum and maximum pixel area sizes
were set. In the other channel, the number of dots (PLA
signals) in each cell as identified by labeling of nuclei
was calculated with the “Measure” command from the
ROI manager using single point as an output type.
Isolation of mitochondria
N2a cells were seeded on 100 mm dishes at 35–40% of
density, followed by incubation with wild type or 5xFAD
serum exosomes. Sixteen hours later, cells were
harvested and washed twice with ice-cold PBS. Cell pel-
lets were then transferred into a Dounce homogenizer
and disrupted with 2 ml of ice-cold mitochondria extrac-
tion buffer [10 mM HEPES, 125 mM sucrose, 0.01%
BSA, 250 mM mannitol, 10 mM EGTA, and protease in-
hibitors (pH 7.2)]. The homogenates were transferred
into a centrifuge tube and cell debris pelleted at 700 x g
at 4 °C for 10 min to enrich for mitochondria. Following
centrifugation under same conditions, supernatants were
transferred to a new ice-cold tube, and then mitochon-
dria pelleted at 10,000 x g for 15 min at 4 °C. The mito-
chondrial pellet was resuspended in 1ml of lipid binding
buffer [20 mM Tris-HCl, 150 mM NaCl, 1 mM EDTA
(pH 7.5), and 1% digitonin, supplemented with protein
inhibitor cocktail (Roche)]. Complete lysis of mitochon-
drial membranes was achieved by sonication. Removal of
insoluble debris was achieved by centrifugation at 10,000
x g for 15 min at 4 °C. The protein concentration in the
supernatants from untreated cells and treated cells was
determined using Bio-rad RC DC™ Protein Assay.
FLICA and cytotoxicity assay
The FLICA 660 Poly Caspase Assay Kit
(ImmunoChemistry Technologies, Minnesota, USA) was
used to determine the presence of early caspase
activation. This in vitro assay employs the fluorescent
inhibitor probe 660-VAD-FMK to label active caspase
enzymes in living cells. N2a cells (0.25–1·105) were incu-
bated with exosomes (0.5–1·104 exosomes/cell) for 6 h at
37 °C. The cells were washed twice with PBS and resus-
pended in RPMI medium with 10% FBS before staining
with 30 × FAM-VAD-FMK for 30min at 37 °C. Cells
were washed with 1 x apoptosis wash buffer prior to be-
ing fixed with 4% paraformaldehyde supplemented with
0.5% glutaraldehyde. The assay was then followed by
PLA as described above.
For LDH cytotoxicity assays, N2a cells were seeded at
a density of 5000 cells/well on 96-well plates in complete
culture medium and were allowed to grow to adequate
confluency. One day before incubation with exosomes,
media were replaced with 2% EV-depleted FBS and kept
overnight. Cells were treated for 12 h with 104 exo-
somes/cell. LDH release was detected using the
CyQUANT™ LDH Cytotoxicity Assay (Thermo Fisher
Scientific, Waltham, MA, USA) according to the manu-
facturer’s protocol.
Western blot and dot blot
For Western blot analysis, samples were mixed with an
equal volume of 2X Laemmli sample buffer. Samples
were resolved by SDS gel electrophoresis on
polyacrylamide gels and transferred to nitrocellulose
membrane (Hybond ECL, Amersham Biosciences, UK).
Non-specific binding sites were blocked with 5% fat-free
dry milk in PBS containing 0.05% Tween-20 followed by
overnight incubation with primary antibodies. For exo-
some characterization we used CD9, CD63, CD81 rabbit
antibodies from ExoAb Antibody Kit (System Biosci-
ences, Inc., Mountain View, CA, USA) after dilution to
1:1000. The following primary antibodies were used for
immmunolabeling on Western blots: anti-flotillin-2
mouse IgG (1:1000, BD Biosciences, California, USA,
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610383), anti-cleaved caspase-3 rabbit IgG (Cell Signal-
ing, Danvers, MA, USA, #9664), anti-VDAC1 goat poly-
clonal IgG (1: 200, Santa Cruz Biotechnology, Inc., CA,
USA), anti-Drp-1 mouse IgG1 kappa light chain (Santa
Cruz, Dallas, TX, USA, sc-271,583). Signals were de-
tected using either pico or femto chemiluminescent
(ECL) horseradish peroxidase (HRP) substrate (Thermo
Fisher, Massachusetts, USA). Blot images were devel-
oped using Azure c600 system (Azure Biosystems, Cali-
fornia, USA).
Exosome immune capturing on beads: affinity
purification using ceramide beads
Twenty μL of protein A sepharose conjugated magnetic
beads were pre-blocked with FcR Blocking Reagent
(MACS, Miltenyi Biotec) for 1 h at room temperature.
After 3-times washing with lipid biding buffer [20 mM
Tris-HCl, 150 mM NaCl, 1 mM EDTA (pH 7.5)], either
anti-ceramide rabbit IgG or control non-specific rabbit
IgG were immobilized on the beads in 1% BSA. Ap-
proximately 2 μg were added to each sample and the re-
action kept mixing overnight on a rotary plate. Next day,
beads were washed 3-times and diluted exosome sam-
ples were added and allowed to incubate with the beads
for 2 h at room temperature. Beads were then collected
using magnetic columns and washed 3-times with deter-
gent free lipid binding buffer. The beads were incubated
with an adequate volume of 2x sample Laemmli buffer,
heated at 90 °C for 10 min and processed for immuno-
blot labeling of GFAP. Aliquots of the flow through were
used for dot blots determing Aβ content and the re-
sidual sample processed for Western blot using 4 x sam-
ple Laemmli buffer. Equal volumes of the samples were
then applied to each well for Western blot analysis. 4 μL
were used for dot blot with the flow through of each
sample.
Mass spectrometric analysis of lipids
Exosomes prepared from serum were taken up in water
and ceramide species were quantified in the
sphingolipidomics (LC-MS/MS) analysis core facility at
the Medical University of South Carolina, Charleston,
SC. The lipid concentration was normalized to lipid
phosphate and exosome number.
Statistical analysis
Clustering analyses were performed with Particle
Explorer V2.1.4 (Particle Metrix Inc., Germany) using
the following features (1. Particle size 2. Position 3. Area
std. 4. Mean intensity std. 5. Trajectory total distance,
std. speed, track time, med- speed, and max-speed). For
the lipid analysis, results were analyzed with Two-way
ANOVA using ceramide species and genetic background
as two independent factors. The effect of exosomes from
two sources (e.g., wild type and 5xFAD) with unequal
sample sizes or unknown variances were analyzed by un-
paired t-test with Welch’s correction. When multiple
comparisons affected by a potential baseline shift in each
sample (e.g., mass spectrometric analysis of ceramide
species) were analyzed, we used the Bonferroni correc-
tion on One-way ANOVA, a statistical test typically ap-
plied to mass spectrometric analyses to exclude false
positives. Other tests such as One-way ANOVA with
Student-Newman-Keuls (SNK) post hoc test or Tukey
correction for comparison of multiple means were ap-
plied when used for similar analyses as described in lit-
erature. Results showing p < 0.05 were reported as
statistically significant. All statistical analysis were done
on Graphpad prism software.
Results
5xFAD mouse and AD patient serum contains exosomes
enriched with ceramide and derived from astrocytes
(astrosomes)
Several studies showed that exosomes cross the blood-
brain-barrier (BBB) carrying toxic and misfolded protein
of CNS origin [25, 64]. These studies also showed that
purification of exosomes from serum or plasma allows
characterization of exosomes from different cell types in
the brain, including astrocytes. We used polymer pre-
cipitation and membrane affinity chromatography to iso-
late exosomes from sera of transgenic mouse model of
AD and AD patients as these isolation methods were
shown to give consistent results when used with plasma
or serum [22, 32, 69]. Due to the limitations in
availability of AD patient serum, we first focused on
characterization of exosomes prepared from serum of
the transgenic mouse model of AD (5xFAD) and wild
type littermates with identical genetic background
(C57Bl/6). 5xFAD mice overexpress presenilins (PS1)
with two FAD mutations (M146L and L286V) as well as
amyloid precursor protein (APP) with three FAD muta-
tions (V717I, I716V, and K670N/M671L) [49]. Nanopar-
ticle tracker analyses (NTA, Zetaview) and cluster
analyses software (Particle Explorer, Particle Metrix,
Mebane, NC) showed that the number of exosomes in
wild type and 5xFAD serum from 9months old mice
was similar (8.47·1011 +/− 3.6·1010 exosomes/250 μl
serum vs. 9.14·1011 +/− 5.1 1010 exosomes/250 μl serum,
N = 6). While the majority of exosomes from wild type
serum was composed of a homogenous population of
vesicles with medium size of 100 nm (Fig. 1a), exosomes
from 5xFAD serum contained an additional vesicle
population of larger size accounting for 37 +/- 4% of the
total population, indicating aggregate formation (Fig. 1b).
Immunoblot analysis was used to validate the presence
of exosomal markers such as tetraspanin proteins
(CD63, C9, and CD81) as well as raft and exosome-
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associated proteins flotillin-1 and flotillin-2, and the
astrocyte marker GFAP (Fig. 1c).
Lipid analysis using mass spectrometry (LC-MS/MS)
showed that 5xFAD exosomes were enriched with
ceramide (4.3 pmoles total ceramide/1011 5xFAD serum
exosomes vs. 2.2 pmoles/1011 wild type serum
exosomes), particularly C16:0, C18:0, C20:0, 22:0, C24:0,
and C24:1 ceramide (Fig. 1d and e, N = 3).
Normalization to lipid phosphate (Fig. 1d) as well as
particle count (Fig. 1e) showed similar enrichment,
confirming that the ceramide composition was
representative for the exosome population in serum. We
also determined ceramide composition and GFAP
association of exosomes in serum from AD patients.
Consistent with the results obtained with mouse serum,
the number of exosomes in serum from healthy controls
and AD patients was similar (2.05·1011 +/− 5.1·109
exosomes/250 μl serum vs. 1.85·1011 +/− 6.2·109
exosomes/250 μl serum. N = 3). There was a population
of larger particles which appeared to be similar to that
in 5xFAD serum (Supplemental Fig. 1A). Supplemental
Fig. 1b shows that the levels of some of the ceramide
species (C16:0, C18:0, C18:1, C20:0, and C20:1
ceramide) were increased in AD patient exosomes, while
others (C22:0 and C24:0 ceramide) were not. This
difference in the ceramide profiles between the 5xFAD
mouse and AD patient serum exosomes could be due to
differences in the activity of ceramide synthases (CerS)
in mice vs. patients. The GFAP level associated with
serum exosomes from AD patients was comparable to
that of healthy controls (Supplemental Fig. 1C). It is
possible that characteristics such as exosome
enrichment with GFAP are more profound with 5xFAD
serum exosomes because of the severe AD pathology
phenotype that may not be completely comparable to
that of late onset AD patients. Therefore, our results
suggest that the main difference between 5xFAD and
AD serum exosomes to those from wild type and human
controls is a proportion of exosomes enriched with
particular ceramides.
Serum astrosomes are associated with Aβ and sensitive
to novel ceramide analogs
To further characterize the proportion of ceramide-
enriched exosomes, we used anti-ceramide rabbit IgG
immobilized on protein A sepharose beads to separate
ceramide-enriched exosomes from other exosome popu-
lations in serum. Figure 2a shows that GFAP labeling
was only found with exosomes bound to the beads, while
exosomes in the flow through were GFAP negative.
Fig. 1 5xFAD serum-derived exosomes are enriched with ceramide and associated with GFAP. a-b Cluster analysis of wild type (WT) and 5xFAD
serum-derived exosomes after Nano Particle Tracking analysis showing a population of larger exosomes in 5xFAD serum. N = 3 (c) Immunoblot of
exosome markers CD9, CD63, CD81, flotillin-1, and flotillin-2, demonstrating higher amounts of GFAP in 5xFAD exosomes compared to WT
exosomes. d-e Ceramide species profile determined using LC-MS/MS of WT and 5xFAD serum-derived exosomes and normalized to lipid
phosphate content (d) and to exosome count (e) Asterisks denote significance (p < 0.05) after Two-way ANOVA followed by Bonferroni
correction (N = 3)
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Control rabbit IgG did not bind any serum-derived exo-
somes confirming specificity of the binding reaction for
ceramide-enriched astrosomes. Wild type serum also
contained astrosomes retained by anti-ceramide anti-
body, however, at lower concentration as indicated by
weaker immunolabeling for GFAP. NTA analysis showed
that retention by anti-ceramide beads reduced the num-
ber of exosomes by 2.3+/− 0.3% from wild type and
9.2+/− 0.8% (N = 3) from 5xFAD serum indicating that
the proportion of ceramide-enriched astrosomes in
5xFAD serum is ≃ 4-fold higher than that in wild type
serum.
Next, we tested if ceramide-enriched exosomes in
serum were associated with Aβ by determining the
amount of Aβ retained on anti-ceramide beads vs. that
in flow through. Immunolabeling using dot blots showed
that only the flow through of beads with control IgG
contained Aβ42, while amyloid peptide was retained on
anti-ceramide beads (Fig. 2b). Consistent with immuno-
labeling for GFAP, the amount of Aβ was 2.2-fold higher
in 5xFAD serum than that from wild type mice (not
shown). Since ceramide-enriched exosomes were associ-
ated with GFAP as well as Aβ we concluded that 5xFAD
serum contained a proportion of astrosomes enriched
with ceramide and associated with Aβ.
Enrichment of astrosomes with ceramide suggested
that this lipid participates in association of Aβ to
astrosomes. This hypothesis is consistent with our
previous studies showing that anti-ceramide IgG pre-
vented aggregation of exosomes induced by incubation
with Aβ [15]. Figure 2c shows that incubation with anti-
ceramide IgG abolished the proportion of larger sized
vesicles in the preparation of 5xFAD exosomes, similar
to the effect of anti-ceramide antibody on aggregation of
Aβ-associated astrosomes derived from cell culture
media. We also found reduction of vesicle size by 17%
(N = 4) when adding the novel ceramide analog N-oleoyl
serinol (S18) but not N-palmitoyl bisethanolamine (B16,
structures are shown in Supplemental Fig. 1 D) to
5xFAD exosomes, suggesting that S18 is a ceramide
mimic that disrupts Aβ association and aggregation of
astrosomes, probably by interfering with the ceramide-
mediated binding of Aβ to astrosomes.
Astrosomes are taken up by neural cells and transport Aβ
and ceramide to mitochondria
To test if serum-derived exosomes are up taken by
neural cells, we incubated neuronally differentiated N2a
cells, a mouse neuroblastoma cell line, with exosomes la-
beled with the fluorescent membrane-binding dye
PKH67. N2a cells were used as an in vitro model since
neuroblastoma cells are an established model for neur-
onal uptake and biological activity of exosomes [33, 36].
Key results were then confirmed using primary cultured
neurons. Supplemental Fig. 2A-C shows that both, wild
type and 5xFAD serum-derived exosomes labeled with
Fig. 2 5xFAD serum astrosomes associated with Aβ form aggregates, which is reduced by the novel ceramide analog S18. a Gel electrophoresis after
immune capturing of exosomes on beads using either ceramide antibody or control IgG and probing with anti-GFAP antibody. Blot is
representative of the results from three independent experiments. b Dot blot against Aβ using flow through for the same experiment. c Size
distribution of wild type (WT), 5xFAD, and 5xFAD exosomes treated with anti-ceramide IgG. d Size distribution of WT, 5xFAD, and 5xFAD
exosomes treated with the novel ceramide analog S18. Particle diameter of each sample is represented as ±SEM, two-way ANOVA,
*p < 0.05. N = 4
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PKH67 are taken up by N2a cells and primary cultured
neurons. Cells incubated with wild type serum-derived
exosomes were labeled for ceramide, but not or only
weakly for GFAP (Fig. 3a and c), while cells incubated
with 5xFAD serum exosomes were colabeled for cer-
amide and GFAP (Fig. 3b and c). Since there were no or
only few cells that showed increased ceramide signals
without being colabeled for GFAP, our data demonstrate
that N2a cells effectively take up ceramide-enriched
astrosomes.
Next, we tested whether astrosomes transported Aβ
into N2a cells. Using immunocytochemistry, we detected
Aβ signals in N2a cells incubated with 5xFAD exosomes
but not with those from wild type serum (Fig. 3d and e).
The Aβ signal colocalized with labeling for flotillin-2 (ar-
rows in Fig. 3e), suggesting that astrosomes delivered Aβ
into N2a cells. To further confirm the validity of these
results, we used a proximity ligation assay (PLA) for
complex formation between ceramide and Aβ in mem-
brane dye PKH67-labeled exosomes taken up by N2a
cells [35, 37]. Supplemental Fig. 3A-D shows that PLA
signals colocalized with PKH67 labeling and were only
observed in cells incubated with 5xFAD exosomes.
We then tested if serum exosomes from AD patients
showed similar uptake characteristics as 5xFAD
exosomes. N2a cells incubated with AD patient
exosomes showed colocalization of ceramide and
flotillin-2 (Fig. 4b). While endogenous ceramide and
flotillin-2 were detectable in exosome-treated cells, we
lowered the pertinent fluorescence signals to that of
background to specifically monitor ceramide and
flotillin-2 contributed by exosomes. Cells incubated with
exosomes from healthy controls showed ceramide and
flotillin-2 and ceramide labeling, however, at much lower
intensity than cells incubated with AD exosomes
(Fig. 4a). These results indicated that exosomes from hu-
man serum, particularly when derived from AD patients,
were taken up and transported ceramide into cells.
Several studies showed that mitochondria are affected
by Aβ [9, 45, 57]. Using immunocytochemistry for Aβ
and Tom-20, we showed that Aβ was labeled in mito-
chondria of hippocampal tissue from AD patients
Fig. 3 5xFAD serum contains Aβ-associated astrosomes that are taken up by neural cells Representative images of N2a cells incubated with
exosomes isolated from wild type (WT) (a, d) or 5xFAD serum (b, e)and coimmunolabeled with antibodies against GFAP and ceramide (a, b) or
flotillin-2 and Aβ (d, e). Arrows point at cells with uptake of Aβ-associated exosomes. The Pearson’s correlation coefficient was calculated to
compare colocalization of GFAP and ceramide (c) or flotillin-2 and Aβ signals (f) in WT (open bar) and 5xFAD (closed bar). Welch’s t-test,
*p < 0.05. N = 6
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Fig. 4 Serum-derived exosomes from AD patients transport ceramide into cells. Immunofluorescence images of N2a cells incubated with either (a)
healthy control or (b) AD patient serum-derived exosomes labeled with anti-ceramide and flotillin-2 antibodies. (c) fluorescence intensities for the
ceramide signal. N = 6. Student t-test with Welch’s correction, *p < 0.05, **p < 0.01
Fig. 5 Serum-derived exosomes from 5xFAD mice and AD patients shuttle Aβ to mitochondria in N2a cells and neurons. Immunofluorescence images
of N2a cells incubated with either (a) wild type or (b) 5xFAD serum-derived exosomes and then labeled with flotillin-2 and Tom-20 antibodies. (e)
Pearson’s correlation coefficient for colocalization of flotillin-2 and Tom-20. N = 6. Student t-test with Welch’s correction. *p < 0.05. c, d Neurons
differentiated from human iPS cells and incubated with control healthy human (c) or AD patient exosomes (d) showing that only AD patient
exosomes shuttle Aβ to mitochondria in neurons (arrows). f Pearson’s correlation coefficient for colocalization of Aβ with Tom-20. N = 6. Student
t-test with Welch’s correction. **p < 0.01. g as in d, but additional labeling of AD patient exosomes with Vybrant CM diI showing mitochondrial
clustering (arrows) induced by Aβ-associated exosomes. Bottom image shows detail of (g)
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(arrows in Supplemental Fig. 4A), suggesting that Aβ is
transported to mitochondria in AD brain. To investigate
exosome-mediated transport of Aβ, we first tested if
5xFAD serum-derived exosomes are transported to
mitochondria. Figure 5a, b and e shows that the exo-
some marker flotillin-2 colocalized with the mitochon-
drion marker Tom-20 in 5xFAD exosome-incubated
N2a cells. The flotillin fluorescence signal was analyzed
after subtracting intrinsic signals, thereby eliminating
the possibility that the colocalization resulted from the
fluorescence signal of endogenous flotillin with mito-
chondria. Colabeling and Pearson’s coefficient for colo-
calization were significantly, but only moderately (about
20%) lower when exosomes from wild type serum were
used (Fig. 5b and e), suggesting that transport of exo-
somes to mitochondria is not critically dependent on Aβ
association.
We then tested if serum-derived exosomes from AD pa-
tients and healthy controls matched for sex, age, and body
matrix index (BMI) transported Aβ to mitochondria in
neurons differentiated from human iPS cells. Figure 5d
and f shows that Aβ colocalized with Tom-20 in AD pa-
tient exosome-treated N2a cells, while there was no Aβ
signal detectable when cells were incubated with serum
exosomes from healthy controls (Fig. 5c and f). AD patient
exosomes labeled with Vybrant CM diI also colocalized
with Aβ and Tom-20, demonstrating that exosomes ef-
fectively transported Aβ to mitochondria (Fig. 5g). Mito-
chondria appeared to be clustered, suggesting that uptake
of AD patient-derived exosomes led to mitochondrial
damage in neurons.
Astrosomes induce Aβ-VDAC1 complex formation, which
activates caspases
Our observation that 5xFAD mouse and AD patient
serum exosomes induced clustering of mitochondria in
N2a cells and primary cultured neurons prompted us to
investigate if Aβ-associated astrosomes are neurotoxic
by inducing mitochondrial damage. To test if astrosomes
themselves were neurotoxic we analyzed mitochondrial
clustering and fragmentation of neuronal processes, and
performed TUNEL assays after incubation of primary
cultured neurons from mouse brain with astrosomes,
Aβ, and Aβ pre-incubated with astrosomes (Fig. 6a-f).
The number of TUNEL positive cells was increased by
2.6-fold (Fig. 6f) when cells were incubated with Aβ-
associated astrosomes, concurrent with mitochondrial
clustering (arrows in Fig. 6e) and 5.9-fold enhanced frag-
mentation of neuronal processes (Fig. 6c) as determined
by β-tubulin labeling. This result showed that astro-
somes themselves were only marginally toxic, but they
significantly enhanced neurotoxicity of Aβ.
Mitochondrial dysfunction is known to be a critical
factor in induction of neurotoxicity leading to
neurodegeneration in AD [11, 19, 51]. One of the
previously described targets for Aβ is mitochondrial
voltage-dependent anion channel 1 (VDAC1), a mito-
chondrial gatekeeper for ADP/ATP and calcium
Fig. 6 Neurotoxic effect of Aβ42/astrosome complexes on primary neuronal cultures. Representative single-focal-plane images of β-tubulin and Tom-
20 labeling obtained with control (a), Aβ42 (b), astrosome (d), or Aβ42/astrosome-incubated (e) primary cultured mouse neuron. Arrows indicate
mitochondrial clusters. c Average normalized density of β-tubulin labeling reveals that the greatest loss occurs in cultures treated with Aβ42/
astrosome complexes. N = 6. One-way ANOVA with Student-Newman-Keuls (SNK) post hoc test). ***p < 0.001, **p < 0.005, *p < 0.05). f TUNEL assay
detected a 2.6-fold increase in neuronal cell death when Aβ42 and astrosomes were combined (N = 4. One-way ANOVA with SNK post hoc test)
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localized in the outer mitochondrial membrane [50, 65].
We tested if astrosome-associated Aβ interacted with
VDAC1 and induced mitochondrial dysfunction. PLAs
using antibodies to VDAC1 and Aβ showed a 6-fold in-
crease in the number of signals indicating complex for-
mation between VDAC1 and Aβ when N2a cells were
incubated with exosomes from 5xFAD serum as com-
pared to those from wild type serum (Fig. 7a-c). PLA
signals were clustered (arrows in Fig. 7b) consistent with
mitochondrial clustering induced by Aβ-associated
astrosomes. Mitochondrial damage was confirmed by
up-regulation of the fission protein Drp-1 in mitochon-
dria isolated from N2a cells incubated with 5xFAD
serum exosomes (Fig. 7d). Figure 7e and f shows that in
N2a cells and primary cultured neurons incubated with
exosomes from 5xFAD mice or AD patient serum, PLA
signals were colocalized with Tom-20, concurrent with
mitochondrial clustering. These results confirm that
astrosome-associated Aβ formed complexes with
mitochondrial VDAC1 and leads to mitochondrial
damage. PLA signals for VDAC1-Aβ complexes were
also found in the vicinity of amyloid plaques of AD
brain tissue, suggesting that VDAC1-Aβ complex
formation contributes to AD pathology in vivo (Supple-
mental Fig. 4B).
Since 5xFAD mouse and AD patient serum exosomes
transported ceramide into cells (Figs. 3b and 4b) we
tested if VDAC1-Aβ complex formation was colocalized
with ceramide. Figure 8a-c shows that in primary cul-
tured neurons incubated with 5xFAD serum exosomes
(Fig. 8b) or AD patient exosomes (Fig. 8c), PLA signals
for formation of complexes of VDAC1 with Aβ were
colocalized with ceramide (arrows). Neurons incubated
with wild type serum exosomes showed no or only a few
PLA signals and they were not colocalized with ceramide
(Fig. 8a). This result suggested that VDAC1-Aβ complex
formation was associated with ceramide derived from
exosomes.
Next, we tested if exosome-mediated VDAC1-Aβ
complex formation led to activation of caspase 3, a hall-
mark of neurotoxicity and apoptosis. Figure 9a and b
shows that in N2a cells incubated with AD patient
serum (Fig. 9a) or 5xFAD mouse serum (Fig. 9b) exo-
somes, PLA signals for VDAC1-Aβ complexes were
colocalized with labeling for activation of caspases
(FLICA assays), suggesting induction of apoptosis.
Fig. 7 Aβ-associated exosomes mediate complex formation between VDAC1 and Aβ and induce mitochondrial damage. a, b Representative
immunofluorescence images of N2a cells incubated with wild type exosomes (a) or 5xFAD exosomes (b) showing increased number of PLA
signals in cells incubated with 5xFAD exosomes. Right panels show detail from left panel (frame). Each red dot denotes complex formation
between Aβ and mitochondrial VDAC1. Arrows indicate PLA signals in mitochondrial clusters (c) Calculation and comparison of average PLA
signals per cell between wild type and 5xFAD incubations, six images for each condition. Student t-test followed by Welch’s correction. N = 6. p <
0.001 (d) Western blot of mitochondrial protein from N2a cells using antibody against Drp-1 and VDAC1 as a reference protein. e, f Colocalization
between PLA signals for VDAC1-Aβ complexes and mitochondrial marker Tom-20 labeling in N2a cells and primary cultured neurons incubated
with 5xFAD serum exosomes (e) and AD patient serum exosomes (f)
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Activation of caspases was confirmed by immunoblot
analysis for cleaved caspase 3 (Fig. 9d and e). Since the
Aβ content of 5xFAD serum exosomes was approxi-
mately 25 pg Aβ42/10
12 exosomes (calculations based on
ELISA data, not shown), and 104 exosomes/cell were
added to 105 cells in 1 ml of medium, the apparent Aβ
concentration was 5 fmoles/l, which is several orders of
magnitude less than what is commonly used in Aβ
neurotoxicity assays. VDAC1-Aβ complex formation
concurrent with caspase 3 activation was confirmed with
5xFAD serum exosomes and primary cultured neurons
(Fig. 9c), suggesting that association of Aβ to ceramide-
enriched exosomes enhances Aβ neurotoxicity by indu-
cing mitochondrial damage and caspase 3 activation.
Finally, we compared neurotoxicity of 5xFAD serum
exosomes with those from mouse brain tissue before
and after removal of ceramide-enriched astrosomes
using pull down with anti-ceramide antibody. Exosomes
were isolated from brain tissue after perfusion with PBS
to rule out any contamination with serum exosomes.
Analyses using NTA showed that brain tissue-derived
exosomes from wild type and 5xFAD mice were similar
in number (1.5 × 109 exosomes/mg wild type vs. 1.6 ×
109 exosomes/mg 5xFAD brain tissue) and size distribu-
tion (Fig. 10a). Normalized to exosome number, the wild
type and 5xFAD exosomes contained comparable levels
of exosome markers, however, GFAP levels were higher
in 5xFAD exosomes indicative of a higher proportion of
astrosomes in 5xFAD brain tissue (Fig. 10b).
Next, we tested if brain tissue-derived exosomes
showed similar effects on neuronal apoptosis as serum
exosomes. Results of the FLICA assay (Fig. 10c) show
that induction of apoptosis by incubation with 5xFAD
brain exosomes (0.5 × 104 exosomes/cell) was about 3-
fold higher than that with wild type brain exosomes,
consistent with data obtained with exosomes from
serum (Fig. 9). When testing cytotoxicity using a
CyQuant assay we found that normalized on the same
number of exosomes used per cell (104 exosomes/cell)
toxicity of exosomes from 5xFAD brain was 4-fold
higher than that from wild type brain and 3.5-fold higher
than that from 5xFAD serum exosomes. This result
shows that the number of neurotoxic exosomes is highly
elevated in 5xFAD brain and that serum exosomes
Fig. 8 Exosome-induced VDAC1-Aβ complex formation is associated with ceramide Representative immunofluorescence images for PLA signals from
VDAC1-Aβ complexes and ceramide in primary cultured neurons incubated with wild type mouse exosomes (a), 5xFAD mouse exosomes (b), or
human AD patient serum-derived exosomes (c). Images in right panel are details at higher magnification (frames in left panel) with arrows
pointing at PLA signals colocalized with ceramide
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represent a portion of brain exosomes with increased
neurotoxicity. When we removed the portion of
ceramide-enriched exosomes from 5xFAD and wild type
brain tissue and serum, cytotoxicity dropped by half,
demonstrating that enhancement of Aβ neurotoxicity is
mediated by enrichment of Aβ-associated astrosomes
with ceramide.
Discussion
While accumulation of Aβ is a hallmark in human
AD, its causal role in neurotoxicity and cognitive
decline is persistently elusive. Other factors such as tau,
bacterial or viral infection, insulin resistance, and
neuroinflammation are invoked in AD, and yet none of
these factors was proven critical in the onset of the disease
or neurodegeneration [10, 34, 54]. Probably the most
likely explanation for AD pathophysiology is a
multifactorial cascade of events with any of these factors
initiating or amplifying each other during the course of
the disease. This multifactor hypothesis implies that each
factor is necessary, but not sufficient to initiate AD or
cause neurotoxicity. The idea that Aβ or tau require
additional factors critical to mediate or enhance their
neurotoxicity is not surprising. Many studies showed that
Aβ and tau concentrations used to induce neuronal
damage or death in vitro are often orders of magnitude
higher than those found in vivo [7, 38, 40]. In
addition, Aβ and tau concentrations or plaque and
tangle size in vivo are often not correlated with the extent
of neurodegeneration or cognitive decline [7]. Recently,
extracellular vesicles (EVs), exosomes or microvesicles,
were proposed as carrier for transport and uptake of Aβ
and tau into neurons [20, 58]. However, it is not clear how
this uptake may lead to neurodegeneration in AD. In
this study, we show for the first time that exosomes are
not only carrier for Aβ, but also sensitize neurons to
Aβ toxicity.
Fig. 9 5xFAD and human AD patient serum-derived exosomes trigger apoptosis in cells induced by interaction between mitochondrial VDAC1 and Aβ.
Representative immunofluorescence images of N2a cells incubated with (a) AD patient exosomes or (b) 5xFAD mouse serum-derived exosomes.
FLICA assays were followed by PLAs for VDAC1-Aβ complex formation. Images show that cells with VDAC1-Aβ complexes undergo apoptosis
(arrows). c Primary cultured neurons incubated with 5xFAD serum exosomes followed by FLICA assays and PLAs. Arrows indicate neurons
colabeled for VDAC1-Aβ complexes and caspase 3 activation. These cells show pyknic nuclei (condensed DAPI labeling) indicative of apoptois. d
Western blot with N2a cell lysate immunolabeled for cleaved caspase 3 using GAPDH as a reference protein. Blot is representative of three
independent experiments. e Relative fold expression of cleaved caspase 3 normalized to GAPDH. One-way ANOVA followed by Tukey correction.
N = 3. **p < 0.001
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Several studies showed that plasma or serum from AD
mice and patients contains exosomes that are associated
with Aβ, demonstrating that Aβ-associated exosomes
crossed the blood brain barrier (BBB) [29, 41]. In AD pa-
tients, about 23% of these exosomes were found to be
derived from astrocytes, while the remainder was from
neurons. Association of astrocyte-derived exosomes
(termed astrosomes in the current study) with Aβ42 was
shown to be several-fold higher than that of neurons,
suggesting that the primary source of Aβ-associated exo-
somes are astrocytes [30] It was not investigated, how-
ever, if Aβ-associated astrosomes were enriched with
ceramide or taken up by cells and involved in the patho-
physiology of AD. Using a method developed in our
laboratory, lipid-mediated affinity chromatography
(LIMAC) of vesicles with anti-ceramide antibody [3], we
showed for the first time that astrosomes from serum
were ceramide-enriched and associated with Aβ. Nano-
particle tracking analysis (Zetaview) of LIMAC fractions
showed that 9.2% of serum-derived exosomes were Aβ-
associated astrosomes, while the remainder (not bound
by anti-ceramide antibody) were only weakly labeled for
GFAP and likely of neuronal origin. The Aβ content in
these vesicles was approximately 25 pg Aβ42/10
12 exo-
somes, which corresponded to 250 μl of serum (5xFAD
mice). Mass spectrometric (LC-MS/MS) analysis of
serum-derived exosomes showed enrichment with cer-
amide species similar to those found in exosomes re-
leased by primary cultures of astrocytes in vitro [71].
This data prompted us to hypothesize that serum-
derived astrosomes associated with Aβ by a mechanism
similar to that previously published for in vitro-gener-
ated astrosomes.
In previous studies, we showed that anti-ceramide
antibody prevented association of Aβ42 with in vitro-
generated astrosomes [15]. We concluded that ceramide
was critical for binding of Aβ42 to astrosomes, by either
directly interacting with it or facilitating interaction of
Aβ with other components of the vesicle membrane. In
this study, we tested a novel concept using ceramide an-
alogs originally developed in our laboratory to disrupt
binding of Aβ to astrosomes [5]. The novel ceramide
analog N-oleoyl serinol (S18) reduced the average diam-
eter of exosomes from 5xFAD mice. This result suggests
that S18-treated exosomes are less prone to aggregation,
and probably, association of Aβ with exosomes is
resolved.
To date, only a few studies addressed a potential
function of Aβ-associated exosomes in AD. It was shown
that exosomes can spread amyloid between neurons and
that uptake of EVs isolated from the cerebrospinal fluid
or plasma of AD patients impairs mitochondrial
Fig. 10 Ceramide-enriched 5xFAD brain tissue and serum exosomes are neurotoxic. (a) Cluster analysis of wild type (WT) and 5xFAD brain tissue-
derived exosomes after Nano Particle Tracking analysis. N = 3 (b) Immunoblot of exosome markers flotillin-1, Alix-1, CD9, and GFAP,
demonstrating higher amounts of GFAP in 5xFAD exosomes compared to WT exosomes. c FLICA assay shows 3-fold increased rate of apoptosis
induction (cells with activated caspase 3) after incubation for 12 h of N2a cells with 5xFAD brain tissue exosomes compared to WT exosomes.
N = 15, Student t-test with Welch’s correction p < 0.005. d Cytotoxicity (CyQuant) assay shows reduction of neurotoxicity after depletion of
ceramide-enriched exosomes. N = 7, Multiple Student t-test with Welch’s correction p < 0.05
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respiratory function and induces caspase activation [20, 58].
However, it was not shown that Aβ-associated astrosomes
are ceramide-enriched, transported to mitochondria, and
mediate Aβ-binding to a critical mitochondrial protein. Our
previous studies suggested that Aβ-associated astrosomes in-
duce nucleation of amyloid plaques and critically participate
in neurodegeneration [17]. However, consistent with other
reports showing that neurotoxicity is not directly correlated
with plaque size, we hypothesized that Aβ-associated astro-
somes mediate neurotoxicity by a mechanism distinct from
plaque formation.
The results using exosomes from serum of 5xFAD
mice and AD patients show that Aβ-associated astro-
somes are transported to mitochondria. This is demon-
strated by colabeling of Aβ and ceramide with Tom-20
in cells that are also positive for GFAP and flotillin 2
when exposed to serum exosomes from 5xFAD mice or
AD patients, but not from wild type mice or healthy
controls. These cells show mitochondrial damage as
documented by clustering of mitochondria and increased
levels of the mitochondrial fission protein Drp-1. Our
data is consistent with that from previous studies report-
ing that the level of Drp-1 is elevated in AD brain and
neurons exposed to Aβ in vitro [1, 42]. In our previous
studies, we showed that Aβ exposure leads to mitochon-
drial malformation and dysregulation of VDAC1, the
main ADP/ATP transporter in the outer mitochondrial
membrane the level of which is elevated in AD [14, 37,
56, 59]. Our data is consistent with that from previous
studies reporting that Aβ binds to VDAC1 and induces
formation of a pro-apoptotic pore [68]. Using cortical
protein lysates from AD patient and AD mouse model
brains, it was shown by co-immunoprecipitation assay
that Aβ binds to mitochondrial VDAC1 [43]. However,
none of the previous studies investigated the effect of
Aβ-associated exosomes on VDAC1 and its interaction
with Aβ.
To test the role of Aβ-associated exosomes in the
interaction of VDAC1 with Aβ we performed proxim-
ity ligation assays (PLAs) after exposure of N2a cells
and neurons to exosomes from 5xFAD mice and AD
patients as well as wild type mice and healthy con-
trols. Our results show that exosomes from 5xFAD
mouse or AD patient serum lead to PLA signals indi-
cating formation of a complex between VDAC1 and
Aβ. Therefore, we concluded that Aβ-associated exo-
somes induced or mediated complex formation be-
tween VDAC1 and Aβ. Currently, we are investigating
the mechanism by which exosomes induce this
complex formation.
Figure 11 shows a model for endocytotic uptake and
interaction with VDAC1 at mitochondria mediated by
Aβ-associated astrosomes. Aβ-associated astrosomes
may either be endocytosed as vesicles or first fuse with
the plasma membrane. In both cases, Aβ (red in Fig. 11)
remains associated with ceramide (green in Fig. 11),
probably in the form of ceramide-rich platforms, a type
of lipid rafts enriched with ceramide [4]. The persistent
association with ceramide explains why Aβ and ceramide
remain colabeled after uptake of Aβ-associated exo-
somes into N2a cells and neurons. Next, Aβ is shuttled
to mitochondria, which is probably mediated by vesicu-
lar transport, either by Aβ-associated endosomes or
other types of vesicular compartments such as aberrant
autophagosomes [46, 48, 61, 73]. Finally, Aβ is imported
into mitochondria to interact with VDAC1, which in-
duces a pro-apoptotic pore that leads to release of cyto-
chrome c and activation of caspases [68]. While
interaction of Aβ with VDAC1 and formation of the
pro-apoptotic pore was reported, the role of ceramide
and exosomes in this process has not yet been
investigated.
Ceramide was invoked in neuronal Aβ release and
formation or secretion of exosomes from astrocytes [15–18].
Our studies showed that ceramide is instrumental for
interaction of Aβ with astrosomes. In the novel mechanism
depicted in Fig. 11, ceramide may critically participate in
several steps of uptake, transport, and mitotoxicity of Aβ.
Firstly, association of Aβ with ceramide in the astrosomal
membrane may induce a specific Aβ isoform or aggregate
promoting endocytosis. This hypothesis is consistent with
our observation that a proportion of exosomes from serum
of 5xFAD mice or AD patients form aggregates. Secondly,
ceramide may critically participate in neuronal endocytosis
and transport of Aβ to mitochondria. In numerous studies, it
was shown that fluorescently labeled ceramide was taken up
by endocytosis and then transported to specific
compartments, mainly the Golgi apparatus [27, 31, 52].
Albeit the reason for Golgi accumulation is unclear, other
studies support the idea that ceramide guides transport of
endosomes to specific compartments, which may include
those interacting with mitochondria [26, 72]. It should be
noted that our previous studies showed that uptake of Aβ42
by glial cells is reduced by at least 50% when associated with
exosomes, suggesting that uptake of Aβ-associated exosomes
as observed in our current study is specific for neurons and
potentially mediated by ceramide [17]. Thirdly, ceramide
may participate in import of Aβ into mitochondria, e.g., by
fusing Aβ-associated astrosomes to the outer mitochondrial
membrane, and binding to VDAC1. Interaction of either
ceramide or Aβ with VDAC1 was demonstrated by several
studies from our and other laboratories [24, 37, 43, 44].
Alternatively, membranes closely associated with the outer
mitochondrial membrane such as mitochondria-associated
membranes (MAMs) may take part in the interaction of Aβ
with VDAC1. Fourthly, ceramide may facilitate formation of
a pro-apoptotic pore that is associated with the VDAC1-Aβ
complex. VDAC1 oligomers as well as ceramide channels
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were reported to partake in pro-apoptotic pores at mito-
chondria [28, 66], however, the involvement of Aβ-
associated and ceramide-enriched exosomes in formation of
these pores was not discussed yet. Our observation that
VDAC1-Aβ complexes are colocalized with ceramide at
mitochondria suggests a novel mechanism by which associ-
ation of VDAC1 with ceramide and Aβ induces or facilitates
pro-apoptotic pore formation. Finally, since association of
Aβ with exosomes is remarkably stable and persists during
passage through the BBB into the blood stream, the propor-
tion of Aβ-associated exosomes may participate in systemic
distribution and potentially, reuptake of Aβ and its spreading
throughout the brain.
Our data show that 5xFAD brain-derived and
ceramide-enriched exosomes are neurotoxic and serum
contains a proportion of these exosomes crossing the
BBB. However, it is conceivable that these exosomes
acquire additional toxic factors during their passage
through the blood stream. Therefore, Aβ-associated exo-
somes in serum may not only be a biomarker and “win-
dow” to the brain, but actively participate in spreading
AD pathology and contributing to Aβ neurotoxicity after
reuptake into the brain. While we utilized serum-derived
exosomes in our in vitro experiments to elucidate the
proposed mechanism, studies are planned to further test
the significance of ceramide-enriched exosomes for Aβ
neurotoxcity in vivo. These studies will address the func-
tion of different ceramide species in neurotoxicity, par-
ticularly when comparing 5xFAD mice with AD patients
and the in vivo significance of systemic distribution and
reuptake of Aβ-associated astrosomes. Here we present
for the first time experimental evidence for our hypoth-
esis that ceramide and Aβ act synergistically to target
VDAC1 and induce caspase activation, ultimately lead-
ing to neuronal malfunction and apoptosis. Therefore,
Aβ-associated astrosomes assisting in Aβ uptake, trans-
port, and mitotoxicity are a novel key factor in sensi-
tizing neurons to Aβ and a potential pharmacological
target to prevent neurodegeneration in AD.
Current pharmacological approaches exclusively aim
at interfering with ceramide generation using inhibitors
for enzymes in ceramide metabolism [8, 39, 60]. The
most prominent example is GW4869, an inhibitor for
neutral sphingomyelinase 2 (nSMase2) we have shown
to reduce plaque formation and improve cognition in
male 5xFAD mice [15]. We previously reported that the
nSMase2- deficient 5XFAD mice (fro;5XFAD) showed a
reduced number of brain exosomes, ceramide levels,
glial activation, total Aβ42 and plaque burden, and
improved recognition in a fear-conditioned learning task
Fig. 11 Potential mechanism of neurotoxicity induced by Aβ-associated astrosomes. Aβ secreted by neurons (red) binds to ceramide-enriched
exosomes secreted by astrocytes (astrosomes, green). Aβ-associated astrosomes are endocytosed by neurons and transported to mitochondria.
The vesicles fuse with the outer mitochondrial membrane and mediate binding of Aβ to VDAC1. A pro-apoptotic pore, probably associated with
ceramide, is formed which leads to activation of caspases and induction of neuronal cell death
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[17]. In future studies, we will specifically address the
function of astrocyte-derived exosomes in Aβ neurotox-
icity by including mice with astrocyte-specific deletion of
nSMase2 as well as knockouts of individual ceramide
synthases.
While enzyme inhibitors are promising as lead
compounds interfering with ceramide metabolism in
AD, alternative pharmacological approaches targeting
ceramide but not depending on enzyme inhibition may
offer additional benefits. About 20 years ago, our
laboratory designed and synthesized novel ceramide
analogs of the β-hydroxy alkylamine type, particularly
N-oleoyl serinol [6] (S18) that do not inhibit ceramide
generation, but interfere with binding of ceramide to its
protein interaction partners such as atypical protein kin-
ase C λ/ξ [6]. These analogs were shown to be non-toxic
to normal cells, but induce apoptosis in cancer cells [5].
We hypothesized that novel ceramide analogs may also
interfere with binding of Aβ to ceramide in astrosomes,
thereby providing a novel therapeutic approach prevent-
ing astrosome-mediated spreading and uptake of Aβ,
and sensitization of neurons to Aβ. Our data with S18
obliterating exosome aggregates in 5xFAD serum sup-
port this hypothesis, which will also be investigated in
our future research. In summary, our data show for the
first time that astrosomes sensitize neurons to Aβ and
suggest that interfering with binding of Aβ to astro-
somes using novel ceramide analogs may provide a novel
therapeutic strategy for treating AD.
Conclusions
The exact mechanism of amyloid beta (Aβ) peptide
neurotoxicity in Alzheimer’s disease (AD) is not known.
Extracellular vesicles (EVs), specifically exosomes were
recently found to bind and spread Aβ. In this study, we
showed that exosomes secreted by astrocytes (astrosomes)
associated with Aβ and were taken up by neurons and
transported to mitochondria. Aβ-associated astrosomes
were enriched with the sphingolipid ceramide that is sug-
gested to mediate binding of Aβ to voltage-dependent
anion channel 1 (VDAC1), the main ADP/ATP trans-
porter in the outer mitochondrial membrane. The
VDAC1-Aβ complex is known to form an oligomeric pro-
apoptotic pore. Hence, association of Aβ with astrosomes
targeting mitochondria in neurons is a novel mechanism
to enhance Aβ neurotoxicity by inducing apoptosis. Our
data show that this mechanism induced neuronal apop-
tosis at a concentration (5 femtomolar) that is several
orders of magnitudes lower than that achieved with Aβ
without exosomes. Neurotoxic Aβ-associated astrosomes
were isolated from brain tissue and serum indicating that
they cross the blood-brain barrier. Neurotoxicity of brain
and serum astrosomes is critically dependent on ceramide,
suggesting that disruption of Aβ association or other
effects of astrosomes with ceramide analogs offers a new
therapeutic approach to AD.
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